Research Journal of Pharmaceutical Dosage Form and Technology

Manoj K. Baladaniya ¹, Ankit P. Karkar ¹, Nirav V. Patel ¹

Affiliations
1 Department of Pharmaceutical Sciences, Saurashtra University, Rajkot-360005, IN

Abstract

The brain in delicious organ of the body so, it is necessary to protect them. Also it a complex system of the body. Although various research has been done for patient suffering from the fatal CNS disease such as brain tumor, HIV encephalopathy, epilepsy, cerebrovascular disease, neurodegenerative disorders. In clinical experiment it failure to treat properly due to lack of potency but rather method by which deliver a particular dosage form to that part. Treating CNS is particular challenging due to present of formidable barrier such as BBB, is a major bottleneck in drug delivery to brain this can be involve tight junction between endothelial cell result in very high endothelial electric resistance then other body tissue that can be effect on the uptake of drug to brain. In present review various strategies to enhance transport of drug to CNS like, carrier mediated transport, receptor mediated transport, BBB distruption, cell penetrating peptide and targeting therapy, intracerebral, intracerebroventricular and intransal delivery via olfactory and neuronal pathway. In this review brief description of BBB and nasal anatomy can be involve. Among various strategies intra nasal delivery most prefer way to improving delivery of drug via olfactory region, due to highly permeation rate of nasal mucosa and also rapid absorption of drug to produce onset of action high. In that brief description of all possible factor for nasal drug delivery can be involve.

Keywords

Patents, BBB, CNS Drug Targeting Strategies, Intranasal Drug Delivery, Liposome, Nanoparticle, Marketed Product.

Full Text

     

Manoj K. Baladaniya ¹, Ankit P. Karkar ¹, Jatin R. Kambodi ¹

Affiliations
1 Department of Pharmaceutical Sciences, Saurashtra University, Rajkot-360005, IN

Abstract

Glibenclamide, a sulfonylurea derivative is widely used as hypoglycaemic agent. Glibenclamide is a highly permeable class II drug. Hence, rate of oral absorption is often controlled by the dissolution rate in the gastrointestinal(GI)Tract. Therefore,the Liquisolid compact of Glibenclamide has been prepared for the enhancement of dissolution of Glibenclamide. Neusilin US2 was selected as carrier material and Aerosil 200 was selected as coating material. A Central composite factorial design was applied to optimize the drug release profile systematically. The amounts of drug (%) in PEG 400 (X1) and Excipient ratio, R (X2) were selected as independent variables. Angle of repose (Y1), Hardness (Y2) and CPR at 10 min (Y3) were selected as dependent variables. All the batches of Liquisolid compacts showed significance improvement in dissolution of Glibenclamide. Various dissolution parameters like DP10min, %DE10min and MDT of optimized batch and direct conventional tablet were compared. DSC and XRD analysis of pure Glibenclamide, physical mixture and final formulation indicated that the drug was solubilized in non-volatile vehicle and solubilization of Glibenclamide was the main cause of enhancement of solubility of Glibenclamide. Storage of the prepared formulations at 45°C for one month showed no any chemical incompatibility. It was concluded that, Liquisolid compact technique can be a simple and effective to enhance the dissolution of poorly water soluble drug.

Keywords

Liquisolid Compact, Glibenclamide, Neusilin US2, Central Composite Design, Liquid Load Factor, Solubility Enhancement.

Full Text